2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)

Autor: Siena, S., Sartore-Bianchi, A., Karthaus, M., Smith, D., Garcia-Carbonero, R., Van Cutsem, E., Guan, X., Boedigheimer, M., Sidhu, R., Jung, A.S., Oliner, K.S., Tabernero, J., Bardelli, A.
Zdroj: In European Journal of Cancer September 2015 51 Supplement 3:S394-S395
Databáze: ScienceDirect